Ucwaningo lwe-MK-5684 Versus Alternative Next-generation Agent Hormonal ku-Metastatic Castration-resistant Prostate Cancer Post One NHA

Inhloso yalolu cwaningo ukuhlola ukusebenza kahle nokuphepha kwe-opevesostat plus hormone replacement therapy (HRT) uma kuqhathaniswa nenye i-abiraterone acetate noma i- enzalutamide kubahlanganyeli abanomdlavuza wendlala yesinye we-Metastatic Castration-resistant (mCRPC) owake waphathwa ngomenzeli wamahomoni wesizukulwane esilandelayo (NHA). Imibono yocwaningo eyinhloko iwukuthi i-opevesostat iphakeme kunenye i-abiraterone acetate noma i- enzalutamide ngokuphathelene nokusinda kwamahhala kwe-radiographic (rPFS) ngeqembu le-Prostate Cancer Working Group (PCWG) Imibandela Yokuhlola Ukusabela Okuguquliwe Kuma-Solid Tumors (RECIST 1.1) njengoba ihlolwe yi-Blinded androgenval receptor (i-BICRval Independent) Isibuyekezo se-OS Ephakathi (i-BICRval Independent) kanye ne-OS Ephakathi isizinda esibophezelayo se-ligand (AR LBD) ukuguqulwa kwabahlanganyeli abalungile nabangalungile.